Literature DB >> 22000060

Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis.

Rebbekah J Atkinson1, Patricia T Michie, Ulrich Schall.   

Abstract

BACKGROUND: Reduction in a pre-attentive measure of auditory change detection, mismatch negativity (MMN), is one of the most consistent findings in schizophrenia. Recently, our group showed a reduction in MMN to changes in the duration and intensity of background sounds in those within 5 years of illness onset, whereas reduced MMNs to changes in sound frequency were only seen in patients with longer illness duration. In this report, we examine whether reduced MMN, as well as P3a, another index of auditory deviance detection, to duration changes is evident even earlier in the illness, that is, in individuals in the first episode of a psychosis (FEP) and individuals identified as being at ultra-high risk of developing schizophrenia (UHR).
METHODS: Mismatch negativity and P3a were measured in 30 UHR individuals, 10 FEP individuals, and 20 healthy control subjects to both long (100 msec) and short (50 msec) duration deviant sounds.
RESULTS: Mismatch negativity was reduced to both duration deviants not only in the FEP group but also in the UHR group. P3a amplitude was also reduced in the UHR group but at trend level only in FEP. However, MMN and P3a reductions were unrelated in both UHR and FEP groups, suggesting that they reflect distinct deficits.
CONCLUSIONS: These results suggest that MMN, as well as P3a, to duration deviants are reduced in very early stages of a psychotic illness including those in an at-risk mental state. Both should be considered as potential markers of the prodrome.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22000060     DOI: 10.1016/j.biopsych.2011.08.023

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  81 in total

1.  Delayed preattentional functioning in early psychosis patients with cannabis use.

Authors:  Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2012-03-09       Impact factor: 4.530

2.  Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis.

Authors:  Ricardo E Carrión; Barbara A Cornblatt; Danielle McLaughlin; Jeremy Chang; Andrea M Auther; Ruth H Olsen; Daniel C Javitt
Journal:  Schizophr Res       Date:  2015-02-23       Impact factor: 4.939

Review 3.  A review of recent literature employing electroencephalographic techniques to study the pathophysiology, phenomenology, and treatment response of schizophrenia.

Authors:  Gary Marcel Hasey; Michael Kiang
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

4.  Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders.

Authors:  Gregory A Light; Risto Näätänen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-30       Impact factor: 11.205

Review 5.  The prodrome and clinical risk for psychotic disorders.

Authors:  Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

6.  Decreased entropy modulation of EEG response to novelty and relevance in schizophrenia during a P300 task.

Authors:  Alejandro Bachiller; Alba Lubeiro; Álvaro Díez; Vanessa Suazo; Cristina Domínguez; José A Blanco; Marta Ayuso; Roberto Hornero; Jesús Poza; Vicente Molina
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-28       Impact factor: 5.270

7.  Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Curr Top Behav Neurosci       Date:  2014

8.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 9.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

10.  Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls.

Authors:  Anthony J Rissling; Sung-Hyouk Park; Jared W Young; Michelle B Rissling; Catherine A Sugar; Joyce Sprock; Daniel J Mathias; Marlena Pela; Richard F Sharp; David L Braff; Gregory A Light
Journal:  Schizophr Res       Date:  2013-03-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.